• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Anika Appoints Sheryl Conley to Board of Directors

    11/1/21 9:00:00 AM ET
    $ANIK
    $SRGA
    $STIM
    Medical/Dental Instruments
    Health Care
    Industrial Specialties
    Health Care
    Get the next $ANIK alert in real time by email

    BEDFORD, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021.

    Sheryl Conley joins the Anika Board of Directors with over 35 years of orthopedic and healthcare industry experience, most recently as President and CEO of OrthoWorx, Inc., and previously as Group President, Americas and Global Brand Management, and Chief Marketing Officer for Zimmer, Inc. Ms. Conley brings extensive orthopedic medical device industry knowledge with a focus on global brand management, marketing, sales, product development and operations. Ms. Conley will serve on the Audit Committee. This appointment brings the total number of independent directors to seven.

    "We are pleased to have Sheryl join our Board of Directors as Anika executes on its strategy to transform into a leading joint preservation company," commented Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Anika. "I have known Sheryl for many years as an innovator and leader in the orthopedic industry and her commercial experience in orthopedics is second to none. She spent more than 25 years at Zimmer in escalating management roles, including as Group President across a variety of product segments and geographies, during which she provided key leadership in the development and commercialization of over 50 industry leading brands. We are very excited for her to bring those experiences to the Anika Board."

    Jeff Thompson, Anika's Chair of the Board, commented, "Adding Sheryl brings a high degree of industry knowledge, including significant experience in operating fully integrated orthopedic businesses, which will help guide Anika through its transformational journey as it becomes a leading joint preservation company. I look forward to working with Sheryl in her new role."

    Sheryl Conley is currently President and Board Member of AcceLINX, Inc., a musculoskeletal health business accelerator. She also serves on the Board of Directors for Neuronetics, Inc. (NASDAQ:STIM), since October 2019, where she is a member of the Audit and Nominating and Governance Committees. She also serves on the Board for Surgalign, Inc. (NASDAQ:SRGA), since May 2021, where in addition to her role as Chair, she is a member of the Audit Committee. She holds a Bachelor of Science (Biology and Chemistry) and an MBA from Ball State University (IN).

    About Anika

    Anika Therapeutics, Inc. (NASDAQ:ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with physicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. For more information, please visit www.anika.com.

    For Investor Inquiries:

    Anika Therapeutics, Inc.

    Mark Namaroff, 781-457-9287

    Executive Director, Investor Relations and Corporate Communications

    [email protected]



    Primary Logo

    Get the next $ANIK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANIK
    $SRGA
    $STIM

    CompanyDatePrice TargetRatingAnalyst
    Anika Therapeutics Inc.
    $ANIK
    4/17/2025$21.00Buy
    B. Riley Securities
    Anika Therapeutics Inc.
    $ANIK
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    Neuronetics Inc.
    $STIM
    8/13/2024Outperform → Mkt Perform
    William Blair
    Anika Therapeutics Inc.
    $ANIK
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    Anika Therapeutics Inc.
    $ANIK
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    Anika Therapeutics Inc.
    $ANIK
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    Anika Therapeutics Inc.
    $ANIK
    10/14/2022$26.00Equal-Weight
    Stephens
    Anika Therapeutics Inc.
    $ANIK
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    More analyst ratings

    $ANIK
    $SRGA
    $STIM
    SEC Filings

    See more
    • SEC Form SD filed by Neuronetics Inc.

      SD - Neuronetics, Inc. (0001227636) (Filer)

      6/2/25 4:31:33 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Neuronetics Inc.

      8-K - Neuronetics, Inc. (0001227636) (Filer)

      5/28/25 7:11:18 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Anika Therapeutics Inc.

      10-Q - Anika Therapeutics, Inc. (0000898437) (Filer)

      5/9/25 2:30:08 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    $SRGA
    $STIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cascella Robert bought $75,000 worth of shares (100,000 units at $0.75), increasing direct ownership by 28% to 453,098 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      9/13/24 5:02:03 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Muir Glenn P bought $20,000 worth of shares (25,000 units at $0.80), increasing direct ownership by 9% to 289,818 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      9/6/24 5:05:03 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Muir Glenn P bought $21,250 worth of shares (25,000 units at $0.85), increasing direct ownership by 10% to 264,818 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      8/30/24 5:15:02 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $ANIK
    $SRGA
    $STIM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to one new non-executive employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, a

      6/19/25 7:00:56 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial Program

      MALVERN. Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, is proud to share two significant updates underscoring its ongoing commitment to clinical excellence and innovation in mental health care. This week, NeuroStar will attend the 13th Annual Clinical TMS Society (CTMSS) Meeting, taking place June 11–14 in San Diego, CA as a Silver Sponsor. NeuroStar will present two poster presentations derived from the TrakStar® data set, the largest real-world outcomes database in TMS. Data hi

      6/10/25 8:31:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 2, 2025, Anika granted non-statutory stock options ("Options") covering an aggregate of 2,500 shares of common stock at a per share exercise price of $11.45, which equaled the closing price of common stock on the Nasdaq Global Select Market ("Closing Price") on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation

      6/5/25 5:00:54 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    $SRGA
    $STIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & COO Griffin Stephen D. converted options into 12,840 shares and covered exercise/tax liability with 3,769 shares, increasing direct ownership by 1,134% to 9,871 units (SEC Form 4)

      4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

      6/5/25 5:01:13 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Director Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 27% to 140,890 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:18 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Conley Sheryl L was granted 30,000 shares, increasing direct ownership by 16% to 214,390 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:13 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $ANIK
    $SRGA
    $STIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on Anika Therapeutics with a new price target

      B. Riley Securities initiated coverage of Anika Therapeutics with a rating of Buy and set a new price target of $21.00

      4/17/25 8:32:06 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Barrington Research reiterated coverage on Anika Therapeutics with a new price target

      Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously

      11/1/24 10:25:08 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Neuronetics downgraded by William Blair

      William Blair downgraded Neuronetics from Outperform to Mkt Perform

      8/13/24 10:26:16 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $ANIK
    $SRGA
    $STIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Neuronetics Inc.

      SC 13D - Neuronetics, Inc. (0001227636) (Subject)

      12/17/24 9:15:11 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      11/14/24 1:42:23 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      11/14/24 11:17:47 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $ANIK
    $SRGA
    $STIM
    Financials

    Live finance-specific insights

    See more
    • Anika Reports First Quarter 2025 Financial Results

      First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 ResultsAnika announced first quarter reven

      5/9/25 7:05:26 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025

      BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 63463. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.co

      4/25/25 9:00:59 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

      MALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2025 financial and operating results prior to market open on Tuesday, May 6, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/knieqjnc. To listen to the conference call on your telephone, participants may register for the

      4/22/25 8:30:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $ANIK
    $SRGA
    $STIM
    Leadership Updates

    Live Leadership Updates

    See more
    • Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

      MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) --  Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strate

      6/2/25 4:30:00 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

      Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

      6/26/24 8:00:00 AM ET
      $A
      $ANIK
      $AVNT
      $MASI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical/Dental Instruments
      Health Care
    • Anika Enters into Cooperation Agreement with Caligan Partners

      Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP ("Caligan"). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed to the Company's Board of Directors, effective immediately. Messrs. Capper and Jellison have nearly 50 years of combined experience building value and driving transformative growth at MedTech compa

      5/28/24 4:05:00 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care